Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Context Imaging and post-mortem studies provide converging evidence that subjects with schizophrenia (SZ) have a dysregulated trajectory of frontal lobe myelination. Prior MRI studies suggested that early in treatment of SZ, antipsychotic medications initially increase frontal lobe white matter (WM) volume, which subsequently declines prematurely in chronic stages of the disease. Insofar as the trajectory of WM decline associated with chronic disease may be due to medication non-adherence, it may be modifiable by long acting injection (LAI) formulations. Objectives Examine the impact of antipsychotic formulation on the myelination trajectory during a randomized six-month trial of LAI risperidone (RLAI) versus oral risperidone (RisO) in first-episode SZ subjects. Design Two groups of SZ subjects (RLAI, N=11; and RisO, N=13) that were matched in pre-randomization oral medication exposure and 14 healthy controls (HCs) were prospectively examined. Frontal lobe WM volume was estimated using inversion recovery (IR) MRI images. A brief neuropsychological battery that focused on reaction times was performed at the end of the study. Main outcome measure WM volume change scores. Results WM volume remained stable in the RLAI and decreased significantly in the RisO groups resulting in a significant differential treatment effect, while the HC had a WM change intermediate and not significantly different from the two SZ groups. WM increase was associated with faster reaction times in tests involving frontal lobe function. Conclusions The results suggest that RLAI may improve the trajectory of myelination in first-episode patients and have a beneficial impact on cognitive performance. Better adherence provided by LAI may underlie the modified trajectory of myelin development. In vivo MRI biomarkers of myelination can help clarify mechanisms of action of treatment interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Lipid composition of the normal human brain: gray matter, white matter, and myelin
O'Brien, J. S., & Sampson, E. L. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39619-x · Cited by 848
High cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799 · cited 2×
“Myelin is a highly specialized lipid membrane wrapping of axons that has the highest cholesterol content of any brain tissue and increases action potential transmission speed over 100 fold (O’Brien and Sampson, 1965; Rouser et al, 1972; Saher et al, 2005).”
BackgroundUranova, N. A., Vostrikov, V. M., Orlovskaya, D. D., & Rachmanova, V. I. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00181-6 · Cited by 659
Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A., & Bilder, R. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.473 · Cited by 590 · cited 1×
“…(SZ) respond very well to antipsychotics and can achieve high levels of symptom remission within the first year, ranging from 70 to 87% (Boter et al, 2009; Emsley et al, 2007; Lieberman et al, 1993; Nuechterlein et al, 2006; Robinson et al, 1999; Robinson et al, 2004; Saravanan et al, 2010).”
BackgroundSchizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation
Bartzokis, G. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00364-0 · Cited by 179
Self-citationOlivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., & Lam, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.12.002 · Cited by 141 · cited 3×
“…parameters such as number and duration of hospitalizations were observed in RLAI-treated patients who were recently diagnosed with schizophrenia than for those with chronic schizophrenia (Olivares et al, 2009a) suggesting that improving adherence may be particularly important early in the disease.”
BackgroundXu, H. (2010) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2010.00008 · Cited by 108
Cited by
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A., Remington, G. J., Taylor, V. H., Müeller, D. J., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00622 · Cited by 205
“This was attributed to adherence to medication (58) and suggests that perhaps adherence to treatment may impact the extent to which cognitive benefits are seen.”
BackgroundChew, L.-J., Fusar-Poli, P., & Schmitz, T. (2013) · Developmental Neuroscience · doi:10.1159/000346157 · Cited by 154
Bartzokis, G., Lu, P. H., Heydari, P., Couvrette, A., Lee, G. J., Kalashyan, G., Freeman, F., Grinstead, J. W., Villablanca, P., Finn, J. P., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.010 · Cited by 152
Self-citationNeuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Self-citationMyelin, myelin-related disorders, and psychosis
Mighdoll, M. I., Tao, R., Kleinman, J. E., & Hyde, T. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.040 · Cited by 135
Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
“005) with the LAI compared with a control group, but no significant difference was noted between oral APs and the control group.(57) These results support the hypothesis that LAIs promote intracortical myelination and may exert a neuroprotective effect when used in first-episode schizophrenia patients.”
BackgroundResultLong‐acting injectable antipsychotics in early psychosis: a literature review
Emsley, R., Chiliza, B., Asmal, L., Mashile, M., & Fusar‐Poli, P. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12027 · Cited by 61
Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44
“Two prospective randomized trials in firstepisode patients with schizophrenia found that frontal lobe white matter volume changes differed between patients receiving the LAI risperidone than in those receiving oral risperidone;(42,43) in the first of these studies, greater white matter volume in the LAI group was asso…”
Result
Metadata
- Authors
- Bartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., Detore, N. R., Altshuler, L. L., Mintz, J., Ventura, J., Casaus, L. R., Luo, J. S., Subotnik, K. L., & Nuechterlein, K. H.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 132
- Issue
- 1
- Pages
- 35-41
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2131289958
- Cited by
- 96
- References
- 8
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.